Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway

Figure 2

Alisertib significantly enhances the cytotoxic effect and antimetastatic activity of lenvatinib in HCC cells. (a) The cytotoxicity of various concentrations of alisertib and lenvatinib on HepG2 and Hep3B cells when administered alone or in combination. (b) Clonogenicity of HepG2 and Hep3B cells treated with alisertib alone, lenvatinib alone, and in combination. The results (from three independent experiments) were subjected to statistical analysis and are summarized in (c). (d) HepG2 and PLC cells were treated with lenvatinib, alisertib, or both for 24 or 48 hr. A wound-healing assay was then conducted to examine the invasive and metastatic capabilities of HepG2 and PLC cells. The results (from three independent experiments) were subjected to statistical analysis and are summarized in (e). (f) HepG2 and Hep3B cells were treated with lenvatinib, alisertib, or both for 48 hr. Morphological changes in the cells were detected by microscopy (magnification, ×20; scale bars, 50 μm).

(a)

(b)

(c)

(d)

(e)